Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome
Vera Bittner, Michael Szarek, Philip E. Aylward, et al.
Journal of the American College of Cardiology (2020) Vol. 75, Iss. 2, pp. 133-144
Open Access | Times Cited: 386

Showing 1-25 of 386 citing articles:

2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults
Glen J. Pearson, George Thanassoulis, Todd J. Anderson, et al.
Canadian Journal of Cardiology (2021) Vol. 37, Iss. 8, pp. 1129-1150
Open Access | Times Cited: 630
Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association
Gissette Reyes‐Soffer, Henry N. Ginsberg, Lars Berglund, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2021) Vol. 42, Iss. 1
Open Access | Times Cited: 461
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Ninth Special Issue
Laura Connelly‐Smith, Caroline R. Alquist, Nicole A. Aqui, et al.
Journal of Clinical Apheresis (2023) Vol. 38, Iss. 2, pp. 77-278
Closed Access | Times Cited: 271
Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation
Ron C. Hoogeveen, Christie M. Ballantyne
Clinical Chemistry (2020) Vol. 67, Iss. 1, pp. 143-153
Open Access | Times Cited: 199
Lipoprotein(a) and its Significance in Cardiovascular Disease
Freddy Duarte Lau, Robert P. Giugliano
JAMA Cardiology (2022) Vol. 7, Iss. 7, pp. 760-760
Closed Access | Times Cited: 188
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial
Michael Szarek, Vera Bittner, Philip E. Aylward, et al.
European Heart Journal (2020) Vol. 41, Iss. 44, pp. 4245-4255
Open Access | Times Cited: 155
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome
Gregory G. Schwartz, Philippe Gabríel Steg, Michael Szarek, et al.
Circulation (2020) Vol. 141, Iss. 20, pp. 1608-1617
Open Access | Times Cited: 143
Coronary heart disease risk: Low-density lipoprotein and beyond
Gabriel E. Shaya, Thorsten M. Leucker, Steven R. Jones, et al.
Trends in Cardiovascular Medicine (2021) Vol. 32, Iss. 4, pp. 181-194
Closed Access | Times Cited: 140
Managing Atherosclerotic Cardiovascular Risk in Young Adults
Neil J. Stone, Sidney C. Smith, Carl E. Orringer, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 8, pp. 819-836
Open Access | Times Cited: 133
Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol
Calvin Yeang, Ewa Karwatowska‐Prokopczuk, Fei Su, et al.
Journal of the American College of Cardiology (2022) Vol. 79, Iss. 11, pp. 1035-1046
Open Access | Times Cited: 120
Emerging RNA Therapeutics to Lower Blood Levels of Lp(a)
Sotirios Tsimikas, Patrick M. Moriarty, Erik S.G. Stroes
Journal of the American College of Cardiology (2021) Vol. 77, Iss. 12, pp. 1576-1589
Open Access | Times Cited: 117
Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a European Atherosclerosis Society Task Force
Maurizio Averna, Maciej Banach, Éric Bruckert, et al.
Atherosclerosis (2021) Vol. 325, pp. 99-109
Closed Access | Times Cited: 115
Lipoproteins and fatty acids in chronic kidney disease: molecular and metabolic alterations
Heidi Noels, Michael Lehrke, Raymond Vanholder, et al.
Nature Reviews Nephrology (2021) Vol. 17, Iss. 8, pp. 528-542
Closed Access | Times Cited: 113
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation
Stephen J. Nicholls, Steven E. Nissen, Cynthia Griggs Fleming, et al.
JAMA (2023) Vol. 330, Iss. 11, pp. 1042-1042
Open Access | Times Cited: 101
Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?
Florian Kronenberg
Atherosclerosis (2022) Vol. 349, pp. 123-135
Open Access | Times Cited: 85
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice
Marlys L. Koschinsky, Archna Bajaj, Michael B. Boffa, et al.
Journal of clinical lipidology (2024) Vol. 18, Iss. 3, pp. e308-e319
Closed Access | Times Cited: 74
Lipoprotein(a) Is Markedly More Atherogenic Than LDL
Elias Björnson, Martin Adiels, Marja‐Riitta Taskinen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 3, pp. 385-395
Open Access | Times Cited: 71
Lipoprotein(a) in Atherosclerotic Diseases: From Pathophysiology to Diagnosis and Treatment
Stamatios Lampsas, Maria Xenou, Evangelos Oikonomou, et al.
Molecules (2023) Vol. 28, Iss. 3, pp. 969-969
Open Access | Times Cited: 64
Frequent questions and responses on the 2022 lipoprotein(a) consensus statement of the European Atherosclerosis Society
Florian Kronenberg, Samia Mora, Erik S.G. Stroes, et al.
Atherosclerosis (2023) Vol. 374, pp. 107-120
Open Access | Times Cited: 54
Clinical Trial Design for Lipoprotein(a)-Lowering Therapies
Waqas Malick, Sascha N. Goonewardena, Wolfgang Köenig, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 16, pp. 1633-1645
Open Access | Times Cited: 46
Lipoprotein(a) Testing Trends in a Large Academic Health System in the United States
Harpreet Bhatia, Samantha Hurst, Paresh Desai, et al.
Journal of the American Heart Association (2023) Vol. 12, Iss. 18
Open Access | Times Cited: 45
Lipoprotein(a), Oxidized Phospholipids, and Coronary Artery Disease Severity and Outcomes
Thomas Gilliland, Yuxi Liu, Reza Mohebi, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 18, pp. 1780-1792
Closed Access | Times Cited: 44
Computed tomographic angiography in coronary artery disease
Patrick W. Serruys, Nozomi Kotoku, Bjarne Linde Nørgaard, et al.
EuroIntervention (2023) Vol. 18, Iss. 16, pp. e1307-e1327
Open Access | Times Cited: 41
Lipoprotein(a) and Major Adverse Cardiovascular Events in Patients With or Without Baseline Atherosclerotic Cardiovascular Disease
Adam N. Berman, David Biery, Stephanie A. Besser, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 9, pp. 873-886
Closed Access | Times Cited: 30
Single Ascending and Multiple-Dose Trial of Zerlasiran, a Short Interfering RNA Targeting Lipoprotein(a)
Steven E. Nissen, Kathy Wolski, Gerald F. Watts, et al.
JAMA (2024) Vol. 331, Iss. 18, pp. 1534-1534
Closed Access | Times Cited: 25
Page 1 - Next Page

Scroll to top